Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In addition, we announced that we entered into an agreement with Ypsomed to develop and manufacture BHV-1300 in an easy-to-use, autoinjector for self-administration intended for commercialization.”
FILING10-K0001935979-26-000020cik 0001935979
“In May 2024, we announced that we entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") under which we will sponsor and fund the planned combination Phase 1/2 clinical trial, and Regeneron will provide Libtayo.”
FILING10-K0001935979-26-000020cik 0001935979
“In February 2022, we announced that we entered into a definitive agreement with Channel Biosciences, LLC, a subsidiary of Knopp Biosciences, LLC, to acquire a drug discovery platform targeting Kv7 ion channels, adding the latest advances in ion channel modulation to our growing neuroscience portfolio.”
FILING10-K0001935979-26-000020cik 0001935979
“Based on the early results for BHV-1510, we entered into an expanded collaboration agreement with GeneQuantum Healthcare Co. Ltd. ("GeneQuantum"), which provides broad target exclusivity for up to 18 ADC targets incorporating the TopoIx payload.”
FILING10-K0001935979-26-000020cik 0001935979
“In March 2023, we entered into an exclusive, worldwide (excluding China and its territories and possessions) license agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll") (the "Highlightll Agreement"), pursuant to which we obtained the right to research, develop, manufacture and commercialize Highlightll's brain penetrant dual TYK2/JAK1 inhibitor program.”
FILING10-K0001935979-26-000020cik 0001935979
“In January 2022, we entered into an agreement with KU Leuven ("the KU Leuven Agreement") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders.”
FILING10-K0001935979-26-000020cik 0001935979
“In January 2025, Biohaven announced a research collaboration and license agreement with Merus N.V. ("Merus") to co-develop three novel dual-targeting ADCs, leveraging Merus' Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies (the "Merus Agreement").”
FILING10-K0001935979-26-000020cik 0001935979
“In January 2021, we entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel MoDE platform.”
FILING10-K0001935979-26-000020cik 0001935979
“In February 2022, we announced a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel Phase 3 asset.”
FILING10-K0001935979-26-000020cik 0001935979
“Under Dr. Coric's leadership, the Former Parent entered into several strategic arrangements, including its Collaboration and License agreement with Pfizer, Inc. for the development of rimegepant and zavegepant outside of the United States.”
FILING10-K0001935979-26-000020cik 0001935979
Watchlist prices, news filtered to it, and its next report on your desk.
Biohaven Ltd. has 10 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Biohaven Ltd.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Biohaven Ltd.. Customers appear here when Biohaven Ltd. names them, or when a company names Biohaven Ltd. as a supplier in its own annual report.
Prev close 12.33 · gapped above the open, then crossed back over prior close. High/low 12.75 at 5:15 am ET, 11.98 at 11:15 am ET.
Biohaven Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
BHVN (Biohaven Ltd.) has 10 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: REGN +0.24%, in healthcare.